<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003084</url>
  </required_header>
  <id_info>
    <org_study_id>DM97-022</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-DM-97022</secondary_id>
    <secondary_id>NCI-T97-0023</secondary_id>
    <secondary_id>CDR0000065783</secondary_id>
    <nct_id>NCT00003084</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of Taxol/VP-16/Estramustine vs. Ketoconazole/Doxorubicin/Vinblastine/Estramustine in Androgen Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy
      consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus
      doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the clinical benefit of two combination chemotherapy regimens,
      paclitaxel, etoposide, and estramustine vs ketoconazole, doxorubicin, vinblastine, and
      estramustine in patients with androgen independent prostate cancer, as measured by prostate
      specific antigen (PSA)-based response rate, time to progression, and overall survival. II.
      Identify the most promising regimen to use in a phase III trial based on toxic effects,
      PSA-based response rates, and clinical benefit.

      OUTLINE: This is a randomized multicenter study. Patients are stratified according to risk
      group: low volume disease (no more than 2 lesions on bone scan), intermediate volume (more
      than 2 bone lesions confined to axial skeleton), or high volume (bone lesions in appendicular
      skeletal or visceral lesions). Patients are randomized to one of two treatment arms. Arm I:
      Patients receive oral estramustine three times a day and oral etoposide twice daily on days
      1-14 and paclitaxel IV over 1 hour on day 2. Treatment repeats every 21 days. Arm II:
      Patients receive doxorubicin IV on days 1, 15, and 29, vinblastine IV on days 8, 22, and 36,
      oral ketoconazole three times a day on days 1-7, 15-21, and 29-35, and oral estramustine
      three times a day on days 8-14, 22-28, and 36-42. This regimen consists of 6 weeks of
      alternating chemotherapy and 2 weeks rest, for an 8 week course. Treatment continues in the
      absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 92 patients (46 per treatment arm) will be accrued for this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1997</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate specific antigen (PSA)- based Response Rate</measure>
    <time_frame>8 week cycle</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (Estramustine + Etoposide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm I: Oral Estramustine 3 x day + oral Etoposide 2 x day on days 1-14 + Paclitaxel IV over 1 hour Day 2, repeats every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (Chemotherapy + Ketoconazole)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm II: Doxorubicin IV Days 1, 15, and 29, Vinblastine IV Days 8, 22, and 36, Oral Ketoconazole 3 x day on Days 1-7, 15-21, + 29-35, and Oral Estramustine 3 x day on Days 8-14, 22-28, and 36-42; 6 weeks of alternating chemotherapy and 2 weeks rest, for 8 week course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Doxorubicin IV on days 1, 15, and 29.</description>
    <arm_group_label>Arm II (Chemotherapy + Ketoconazole)</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estramustine phosphate sodium</intervention_name>
    <description>Arm I: Oral estramustine three times a day for 21 day cycle.
Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle.</description>
    <arm_group_label>Arm I (Estramustine + Etoposide)</arm_group_label>
    <arm_group_label>Arm II (Chemotherapy + Ketoconazole)</arm_group_label>
    <other_name>Emcyt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Oral etoposide twice daily on days 1-14.</description>
    <arm_group_label>Arm I (Estramustine + Etoposide)</arm_group_label>
    <other_name>VePeside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.</description>
    <arm_group_label>Arm II (Chemotherapy + Ketoconazole)</arm_group_label>
    <other_name>Nizoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV over 1 hour on day 2.</description>
    <arm_group_label>Arm I (Estramustine + Etoposide)</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>IV on days 8, 22, and 36.</description>
    <arm_group_label>Arm II (Chemotherapy + Ketoconazole)</arm_group_label>
    <other_name>Velban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate Androgen
        independent disease progression -Castrate testosterone level of less than 40 ng/dL (if
        medically achieved, treatment must be maintained continuously) -Prostate specific antigen
        (PSA) at least 4 ng/mL and rising on at least 2 consecutive measurements No variant
        histologies such as ductal carcinoma (endometrioid or cribiform) or small cell carcinoma
        Brain metastases controlled

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-3 Life expectancy:
        At least 12 weeks Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count
        at least 100,000/mm3 Hemoglobin greater than 9.5 g/dL (without transfusion support)
        Hepatic: Bilirubin and transaminase less than 2 times the upper limit of normal Renal:
        Creatinine no greater than 2.0 mg/dL OR Estimated creatinine clearance at least 35 mL/min
        Cardiovascular: No clinical history of heart disease Normal ECG OR Ejection fraction (ECHO,
        MUGA, or ventriculography) at least 45% Other: Spinal cord compression controlled No active
        peptic ulcer disease No active, or likely to become active, second malignancy

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior ketoconazole Chemotherapy: No prior
        doxorubicin, vinblastine, estramustine, paclitaxel, or etoposide No greater than one prior
        cytotoxic therapy No other concurrent chemotherapy At least 8 weeks since prior mitomycin
        At least 60 days since prior suramin Endocrine therapy: No antiandrogen therapy such as
        flutamide or nilutamide within 4 weeks (6 weeks for bicalutamide) without response OR
        Progression since antiandrogen withdrawal Prior dexamethasone therapy discontinued
        Radiotherapy: At least 10 weeks since prior strontium Sr 89 and no more than 1 prior
        regimen No concurrent strontium Sr 89 Surgery: Not specified Other: No other concurrent
        therapy for prostate cancer No concurrent H2 blockers, omeprazole, or antacids No
        concurrent terfenadine and astemizole
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall E. Millikan, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center Website</description>
  </link>
  <results_reference>
    <citation>Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J 3rd, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 2003 Mar 1;21(5):878-83.</citation>
    <PMID>12610188</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2004</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Ketoconazole</keyword>
  <keyword>Estramustine</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Vinblastine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Estramustine</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

